ChemDiv Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ChemDiv Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014389
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ChemDiv Inc (ChemDiv), a subsidiary of ChemRar High-Tech Center is a contract research organization that offers chemistry services, hit finding, integrated drug discovery, pharmatech services, disease based models, drug development, and others. The organization also offers chemistry building blocks and screening libraries. It offers customized services for research and development chemistry, biology and to meet various clinical needs of its customers. ChemDiv partners with various large and small pharma and biotech, academia, foundations and screening centers. The organization operates various research and development centers in Russia, Ukraine, and China. ChemDiv is headquartered in San Diego, California, the US.

ChemDiv Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ChemDiv Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ChemDiv Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ChemDiv Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ChemDiv Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
ChemDiv Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ChemDiv Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
ChemDiv Enters into Co-Development Agreement with Context Therapeutics and Torrey Pines Investment 10
Regen BioPharma Enters into Agreement with ChemDiv 11
Janssen Research & Development Enters into Agreement with ChemDiv 12
ChemDiv, Torrey Pines Investment and DZNE Enter into Research Agreement 13
ChemDiv Enters into Agreement with Cystic Fibrosis Foundation Therapeutics 14
Coare Biotech Enters Into Agreement With ChemDiv To Offer Gene-To-Clinic Services 15
ChemDiv Enters Into Research Agreement With Janssen Pharmaceutica And Tibotec Pharma 16
Emerald BioStructures Enters Into Co-Marketing Agreement With ChemDiv 17
ChemDiv Inc – Key Competitors 18
ChemDiv Inc – Key Employees 19
ChemDiv Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Government and Public Interest 21
Aug 17, 2017: Australian researchers make a breakthrough in finding cure for peanut allergy 21
Aug 15, 2017: Potential broad-spectrum antiviral discovered in herpesvirus study 22
Product News 23
Apr 18, 2017: Regen BioPharma Identifies Three New Series of Compounds That Activate NR2F6 23
Mar 23, 2017: Regen BioPharma Provides Update on NR2F6 Small Molecule Optimization Program for Treating Cancer and Arthritis 24
Jan 11, 2016: ChemDiv Announces Achievement of a Development Milestone in a Drug Discovery Collaboration With Janssen 25
Other Significant Developments 26
Oct 09, 2017: China to accept overseas trial data in bid to speed up drug approvals 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
ChemDiv Inc, Pharmaceuticals & Healthcare, Key Facts 2
ChemDiv Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ChemDiv Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ChemDiv Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ChemDiv Inc, Deals By Therapy Area, 2011 to YTD 2017 8
ChemDiv Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ChemDiv Enters into Co-Development Agreement with Context Therapeutics and Torrey Pines Investment 10
Regen BioPharma Enters into Agreement with ChemDiv 11
Janssen Research & Development Enters into Agreement with ChemDiv 12
ChemDiv, Torrey Pines Investment and DZNE Enter into Research Agreement 13
ChemDiv Enters into Agreement with Cystic Fibrosis Foundation Therapeutics 14
Coare Biotech Enters Into Agreement With ChemDiv To Offer Gene-To-Clinic Services 15
ChemDiv Enters Into Research Agreement With Janssen Pharmaceutica And Tibotec Pharma 16
Emerald BioStructures Enters Into Co-Marketing Agreement With ChemDiv 17
ChemDiv Inc, Key Competitors 18
ChemDiv Inc, Key Employees 19

★海外企業調査レポート[ChemDiv Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SOCO International Plc (SIA):石油・ガス:M&Aディール及び事業提携情報
    Summary SOCO International Plc (SOCO) is an oil and gas company that explores, discovers and produces oil and gas reserves. The company offers appraisal and field development services. It provides training and skills and support local communities. SOCO produces and supplies natural resources. SOCO h …
  • Sienna Biopharmaceuticals Inc (SNNA)-医療機器分野:企業M&A・提携分析
    Summary Sienna Biopharmaceuticals Inc (Sienna Biopharmaceuticals) is a biopharmaceutical company that develops innovation therapies for inflammatory skin conditions and aesthetic conditions. It offers topical by design or low systemic exposure technology platform for local treatment Photoparticle th …
  • Bankers Insurance Group:企業の戦略・SWOT・財務情報
    Bankers Insurance Group - Strategy, SWOT and Corporate Finance Report Summary Bankers Insurance Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Intuitive Surgical Inc (ISRG):医療機器:M&Aディール及び事業提携情報
    Summary Intuitive Surgical Inc (Intuitive Surgical) is a provider of robotic-assisted minimally invasive surgery (MIS) devices. Its portfolio encompasses da Vinci Surgical Systems, InSite and Firefly Fluorescence imaging systems (Firefly), instruments and accessories and training technologies. The d …
  • Teva Pharmaceutical Industries Ltd (TEVA):企業の財務・戦略的SWOT分析
    Teva Pharmaceutical Industries Ltd (TEVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • IPCA Laboratories Ltd (IPCALAB):企業の財務・戦略的SWOT分析
    Summary IPCA Laboratories Ltd (IPCA) is a manufacturer and supplier of active pharmaceutical ingredients (API’s), generics and branded formulations. It is one of India's largest formulation exporters and is specialized in anti-malarial and anti-bacterials therapeutic segments. The company offers API …
  • Harmony Gold Mining Co Ltd:企業の戦略・SWOT・財務情報
    Harmony Gold Mining Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Harmony Gold Mining Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • China Oilfield Services Ltd (2883):石油・ガス:M&Aディール及び事業提携情報
    Summary China Oilfield Services Ltd (COSL) is an integrated oilfield services company. Its services cover each phase of offshore oil and gas exploration, development and production. Its products portfolio includes logging and perforation equipment, oilfield chemicals, well completion tools, sand con …
  • Fluidigm Corp (FLDM):企業の財務・戦略的SWOT分析
    Summary Fluidigm Corp (Fluidigm), formerly Mycometrix Corp, develops, manufactures, and markets life science analytical and preparatory systems for mass cytometry, high-throughput genomics, and single-cell genomics markets. The company offers analytical systems and instruments, preparatory instrumen …
  • Nationale-Nederlanden Levensverzekering Maatschappij N.V.:企業の戦略・SWOT・財務情報
    Nationale-Nederlanden Levensverzekering Maatschappij N.V. - Strategy, SWOT and Corporate Finance Report Summary Nationale-Nederlanden Levensverzekering Maatschappij N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the co …
  • Flextronics International Ltd.:戦略・SWOT・企業財務分析
    Flextronics International Ltd. - Strategy, SWOT and Corporate Finance Report Summary Flextronics International Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Probi AB (PROB):製薬・医療:M&Aディール及び事業提携情報
    Summary Probi AB (Probi) is a biotechnology company develops, produces and markets probiotics. The company offers licenses for its technology and sells finished products in bulk. It focuses on products for the improvement of gastrointestinal health and immune system. It distributes its products to l …
  • National Grid Plc (NG):電力:M&Aディール及び事業提携情報
    Summary National Grid Plc (National Grid) is an energy utility. It transmits and distributes electricity and gas. The company owns and operates electricity and gas transmission and distribution networks; and is also the system operator for the Scottish networks. National Grid provides installation a …
  • Noxilizer Inc-医療機器分野:企業M&A・提携分析
    Summary Noxilizer Inc (Noxilizer) is a medical device company that manufactures sterilization equipment. The company’s products include industrial nitrogen dioxide sterilizer and biodecontamination systems. Its services comprise installation, contract sterilization services, and maintenance services …
  • Baxter International Inc (BAX):企業の財務・戦略的SWOT分析
    Baxter International Inc (BAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Hengeler Mueller Partnerschaft von Rechtsanwalten mbB:企業の戦略的SWOT分析
    Hengeler Mueller Partnerschaft von Rechtsanwalten mbB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key com …
  • Arcadia Group Limited:企業の戦略・SWOT・財務分析
    Arcadia Group Limited - Strategy, SWOT and Corporate Finance Report Summary Arcadia Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Tokyo Tatemono Co., Ltd.:企業の戦略・SWOT・財務情報
    Tokyo Tatemono Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tokyo Tatemono Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • MorphoSys AG (MOR):製薬・医療:M&Aディール及び事業提携情報
    Summary MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The company’s pipeline product includes MOR208, MOR202, MOR103, MOR106, and MOR107. It drugs are used for the treatment of various types of cancers, psoriasis, rheumatoid a …
  • Pharma Foods International Co Ltd (2929):企業の財務・戦略的SWOT分析
    Summary Pharma Foods International Co Ltd (Pharma Foods) operates as a manufacturer and marketer of functional food ingredients and health food products. The company provides products such as ovopron, gamma aminobutyric acid, tasty catechin, alpha lipoic acid, bonepep, runpep and folic acid enriched …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆